Analysts’ Viewpoint
The global vasopressin antagonists market is driven by rise in prevalence of diabetes & hypertension and increase in demand for better treatment options. Technological advancements in drug delivery systems are expected to propel market expansion. Furthermore, rise in awareness among patients and healthcare professionals about the benefits of vasopressin antagonists is fueling market growth.
However, stringent regulatory guidelines and high cost associated with these medications are projected to hamper business expansion. Increase in investment in R&D to develop novel vasopressin antagonist drugs with improved efficacy and safety profiles offers lucrative opportunities for market players. Manufacturers are collaborating with pharmaceutical companies and research organizations to develop more effective and low cost medications in order to increase market share.
The function of vasopressin antagonist is to treat different medical conditions, including diabetes insipidus, hypertension, and heart failure. Vasopressin antagonist blocks the action of vasopressin, a hormone that helps regulate the body's water balance, in order to reduce water retention and improve blood pressure. Vasopressin antagonists are available in both oral and injectable forms. Oral vasopressin antagonists are typically taken once or twice daily, while injectable forms are usually prescribed as a single dose.
Common side effects of vasopressin antagonists are headache, dizziness, nausea, and fatigue. In some cases, these drugs could also cause low blood pressure, which can be dangerous. The most commonly used vasopressin antagonist drugs are tolvaptan and conivaptan. Tolvaptan is used to treat hypertension, and conivaptan is used to treat heart failure.
Increase in prevalence of diabetes is propelling the global vasopressin antagonists market size. According to the WHO, the global prevalence of diabetes surged from 108 million in 1980 to 422 million in 2014. Vasopressin antagonists are drugs that act as diuretics and reduce urine production, helping to control blood sugar levels. These work by blocking the action of vasopressin, which is produced by the pituitary gland and is responsible for controlling water reabsorption in the kidneys. Hence, increase in number of people diagnosed with diabetes is fueling vasopressin antagonists market demand to effectively manage the condition.
Rise in awareness about diabetes and its symptoms has increased the number of diagnostic tests performed to detect the disease. This has led to more number of people being diagnosed and seeking treatment. This, in turn, is likely to propel the global vasopressin antagonists market. For instance, in June 2020, the American Diabetes Association launched a new campaign to spread awareness about diabetes and its complications. This campaign is expected to further drive the growth of the market.
In terms of drug type, the tolvaptan segment accounted for the largest global vasopressin antagonists market share in 2022. This is ascribed to superior efficacy and safety profile compared to other drugs in this class. For instance, a study conducted by researchers at the University of California San Francisco found that patients taking vaptan therapy had significantly lower levels of vasopressin than those taking vaprisol. This suggests that tolvaptan is more effective at reducing vasopressin levels than vaprisol. Another study published in the New England Journal of Medicine indicated that patients taking tolvaptan had fewer side effects than those taking vaprisol. These findings demonstrate that tolvaptan is a safer drug for treating vasopressin-related conditions than vaprisol.
Based on application, the nephrogenic diabetes insipidus segment dominated the global market in 2022. This is ascribed to high prevalence rate among patients suffering from diabetes insipidus (DI). According to a report, around 60% of all DI cases are caused by nephrogenic DI, which makes it one of the most common forms of DI globally.
Recent advances in medical technology have enabled doctors to diagnose nephrogenic DI with greater accuracy. This has increased the number of patients suffering from this condition. Additionally, rise in government support for research on nephrogenic DI is bolstering the segment, as it has led to new treatments being developed for this condition, such as oral medications and gene therapy, which have improved patient outcomes significantly.
In terms of distribution channel, the hospital pharmacies segment held leading share of the global vasopressin antagonists market in 2022. This is attributed to convenient and accessible services available in hospital pharmacies. These channels are a part of hospitals, which provide prescription medications and over-the-counter drugs to patients. These provide a range of services, including counseling patients on drug therapies, monitoring patient health & progress, and providing advice on medicine use. Patients can also get their medications refilled and receive advice on proper usage of medications.
Hospital pharmacies are preferred over other distribution channels, such as retail pharmacies and online pharmacies, as these provide convenient and accessible services to patients. These pharmacies are usually staffed by qualified pharmacists and pharmacy technicians, who are trained to handle the medications and help patients with their medication-related needs. Patients are more likely to get accurate advice on their medications from these channels. Furthermore, hospital pharmacies are better equipped to handle complex drug therapies, such as anticoagulants, chemotherapy, and specialized medications, which are not always available at retail or online pharmacies.
Hospital pharmacies are often preferred due to affordability. These pharmacies provide medications at a discount, as they work with various insurance companies in vasopressin antagonists to offer discounts. This makes them more cost-effective than other distribution channels, such as retail and online pharmacies.
As per global vasopressin antagonists market trends, North America dominated the global market in 2022. This is ascribed to rise in prevalence of syndrome of inappropriate secretion of antidiuretic hormone (SIADH) & euvolemic hyponatremia, increase in awareness about the disease, and high healthcare expenditure. According to a study published in the American Journal of Medicine in 2018, prevalence of SIADH in the U.S. was 3.2 per 10,000 persons.
Asia Pacific is projected to be the fastest-growing region during the forecast period. The market in the region is expected to be driven by rise in prevalence of SIADH & euvolemic hyponatremia, increase in awareness about the disease, and surge in government support & reimbursement. For instance, in May 2019, the Government of India approved the listing of Conivaptan, a vasopressin antagonist, in the National List of Essential Medicines. This listing will enable the government to provide free medicines to all sections of society.
The report includes vital information about the leading players in the global market. Companies focus on strategies such as product launches, divestiture, mergers & acquisitions (M&A), and partnerships to strengthen their position in the market. Otsuka, Cumberland Pharmaceuticals, Mayo Clinic, and Hopital du Sacre-Coeur de Montreal are the prominent players operating in the market.
Each of the players in the market report has been profiled in the report based on parameters such as company overview, overview, business strategies, portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Size in 2022 |
US$ 1.7 Bn |
|
Forecast (Value) in 2031 |
More than US$ 2.7 Bn |
|
Compound Annual Growth Rate (CAGR) |
4.9% |
|
Forecast Period |
2023–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global industry was valued at US$ 1.7 Bn in 2022
It is projected to reach more than US$ 2.7 Bn by 2031
The industry is anticipated to grow at a CAGR of 4.9% from 2023 to 2031
Rise in prevalence of diabetes and increase in awareness of diabetes are driving the market
The tolvaptan segment held the largest share in 2022.
North America is expected to account for significant share during the forecast period
Otsuka, Cumberland Pharmaceuticals, Mayo Clinic, and Hospital du Sacre-Coeur de Montreal
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Vasopressin Antagonists Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Vasopressin Antagonists Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Disease Incidence and Prevalence
5.3. Regulatory Approval
5.4. COVID-19 Impact Analysis
6. Global Vasopressin Antagonists Market Analysis and Forecast, by Drug Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Type, 2017–2031
6.3.1. Vaprisol
6.3.2. Tolvaptan
6.4. Market Attractiveness Analysis, by Drug Type
7. Global Vasopressin Antagonists Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Central Diabetes Insipidus
7.3.2. Nephrogenic Diabetes Insipidus
7.3.3. Other Applications
7.4. Market Attractiveness Analysis, by Application
8. Global Vasopressin Antagonists Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Retail Pharmacies
8.3.2. Hospital Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Vasopressin Antagonists Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Vasopressin Antagonists Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Type, 2017–2031
10.2.1. Vaprisol
10.2.2. Tolvaptan
10.3. Market Value Forecast, by Application, 2017–2031
10.3.1. Central Diabetes Insipidus
10.3.2. Nephrogenic Diabetes Insipidus
10.3.3. Other Applications
10.4. Market Value Forecast, by Distribution Channel, 2017–2031
10.4.1. Retail Pharmacies
10.4.2. Hospital Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Drug Type
10.6.2. By Application
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Vasopressin Antagonists Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Type, 2017–2031
11.2.1. Vaprisol
11.2.2. Tolvaptan
11.3. Market Value Forecast, by Application, 2017–2031
11.3.1. Central Diabetes Insipidus
11.3.2. Nephrogenic Diabetes Insipidus
11.3.3. Other Applications
11.4. Market Value Forecast, by Distribution Channel, 2017–2031
11.4.1. Retail Pharmacies
11.4.2. Hospital Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Type
11.6.2. By Application
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Vasopressin Antagonists Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Type, 2017–2031
12.2.1. Vaprisol
12.2.2. Tolvaptan
12.3. Market Value Forecast, by Application, 2017–2031
12.3.1. Central Diabetes Insipidus
12.3.2. Nephrogenic Diabetes Insipidus
12.3.3. Other Applications
12.4. Market Value Forecast, by Distribution Channel, 2017–2031
12.4.1. Retail Pharmacies
12.4.2. Hospital Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Drug Type
12.6.2. By Application
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Vasopressin Antagonists Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Type, 2017–2031
13.2.1. Vaprisol
13.2.2. Tolvaptan
13.3. Market Value Forecast, by Application, 2017–2031
13.3.1. Central Diabetes Insipidus
13.3.2. Nephrogenic Diabetes Insipidus
13.3.3. Other Applications
13.4. Market Value Forecast, by Distribution Channel, 2017–2031
13.4.1. Retail Pharmacies
13.4.2. Hospital Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Drug Type
13.6.2. By Application
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Vasopressin Antagonists Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Type, 2017–2031
14.2.1. Vaprisol
14.2.2. Tolvaptan
14.3. Market Value Forecast, by Application, 2017–2031
14.3.1. Central Diabetes Insipidus
14.3.2. Nephrogenic Diabetes Insipidus
14.3.3. Other Applications
14.4. Market Value Forecast, by Distribution Channel, 2017–2031
14.4.1. Retail Pharmacies
14.4.2. Hospital Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Drug Type
14.6.2. By Application
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2022
15.3. Company Profiles
15.3.1. Otsuka
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Test Drug Type Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Cumberland Pharmaceuticals
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Test Drug Type Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Mayo Clinic
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Test Drug Type Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Hopital du Sacre-Coeur de Montreal
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Test Drug Type Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
List of Tables
Table 1: Global overview of Vasopressin Antagonists
Table 2: Regional overview of Vasopressin Antagonists
Table 3: North America Overview of Vasopressin Antagonists
Table 4: APAC overview of Vasopressin Antagonists
Table 5: Global Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 6: Global Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 7: Global Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 8: Global Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 9: North America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 10: North America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 11: North America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 12: North America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 13: Europe Vasopressin Antagonists Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Europe Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 15: Europe Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 16: Europe Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 17: Asia Pacific Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Asia Pacific Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 19: Asia Pacific Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 20: Asia Pacific Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Latin America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Latin America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 23: Latin America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 24: Latin America Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 25: Middle East & Africa Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 26: Middle East & Africa Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 27: Middle East & Africa Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 28: Middle East & Africa Vasopressin Antagonists Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Vasopressin Antagonists Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Vasopressin Antagonists Market Size (US$ Mn) Forecast, 2017–2031
Figure 03: Global Vasopressin Antagonists Market Value Share, by Drug Type (2022)
Figure 04: Global Vasopressin Antagonists Market Value Share, by Application (2022)
Figure 05: Global Vasopressin Antagonists Market Value Share, by Distribution Channel (2022)
Figure 06: Global Vasopressin Antagonists Market Value Share, by Region (2022)
Figure 07: Global Vasopressin Antagonists Market Value Share, by Drug Type, 2022 and 2031
Figure 08 Global Vasopressin Antagonists Market Attractiveness Analysis, by Drug Type, 2023–2031
Figure 09: Global Vasopressin Antagonists Market Value Share, by Application, 2022 and 2031
Figure 10: Global Vasopressin Antagonists Market Attractiveness Analysis, by Application, 2023–2031
Figure 11: Global Vasopressin Antagonists Market Value Share, by Distribution Channel, 2022 and 2031
Figure 12: Global Vasopressin Antagonists Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 13: Global Vasopressin Antagonists Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031
Figure 14: Global Vasopressin Antagonists Market Value Share, by Region, 2023–2031
Figure 15: Global Vasopressin Antagonists Market Attractiveness Analysis, by Region, 2023–2031
Figure 16: North America Vasopressin Antagonists Market Value Share, by Drug Type, 2022 and 2031
Figure 17: North America Vasopressin Antagonists Market Attractiveness Analysis, by Drug Type, 2023–2031
Figure 18: North America Vasopressin Antagonists Market Value Share, by Application, 2022 and 2031
Figure 19: North America Vasopressin Antagonists Market Attractiveness Analysis, by Application, 2023–2031
Figure 20: North America Vasopressin Antagonists Market Value Share, by Distribution Channel, 2022 and 2031
Figure 21: North America Vasopressin Antagonists Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 22: North America Vasopressin Antagonists Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031
Figure 23: North America Vasopressin Antagonists Market Value Share, by Country, 2023–2031
Figure 24: North America Vasopressin Antagonists Market Attractiveness Analysis, by Country, 2023–2031
Figure 25: Europe Vasopressin Antagonists Market Value Share, by Drug Type, 2022 and 2031
Figure 26: Europe Vasopressin Antagonists Market Attractiveness Analysis, by Drug Type, 2023–2031
Figure 27: Europe Vasopressin Antagonists Market Value Share, by Application, 2022 and 2031
Figure 28: Europe Vasopressin Antagonists Market Attractiveness Analysis, by Application, 2023–2031
Figure 29: Europe Vasopressin Antagonists Market Value Share, by Distribution Channel, 2022 and 2031
Figure 30: Europe Vasopressin Antagonists Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 31: Europe Vasopressin Antagonists Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031
Figure 32: Europe Vasopressin Antagonists Market Value Share, by Country/Sub-region, 2022–2031
Figure 33: Europe Vasopressin Antagonists Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 34: Asia Pacific Vasopressin Antagonists Market Value Share, by Drug Type, 2022 and 2031
Figure 35: Asia Pacific Vasopressin Antagonists Market Attractiveness Analysis, by Drug Type, 2023–2031
Figure 36: Asia Pacific Vasopressin Antagonists Market Value Share, by Application, 2022 and 2031
Figure 37: Asia Pacific Vasopressin Antagonists Market Attractiveness Analysis, by Application, 2023–2031
Figure 38: Asia Pacific Vasopressin Antagonists Market Value Share, by Distribution Channel, 2022 and 2031
Figure 39: Asia Pacific Vasopressin Antagonists Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 40: Asia Pacific Vasopressin Antagonists Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031
Figure 41: Asia Pacific Vasopressin Antagonists Market Value Share, by Country/Sub-region, 2022–2031
Figure 42: Asia Pacific Vasopressin Antagonists Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 43: Latin America Vasopressin Antagonists Market Value Share, by Drug Type, 2022 and 2031
Figure 44: Latin America Vasopressin Antagonists Market Attractiveness Analysis, by Drug Type, 2023–2031
Figure 45: Latin America Vasopressin Antagonists Market Value Share, by Application, 2022 and 2031
Figure 46: Latin America Vasopressin Antagonists Market Attractiveness Analysis, by Application, 2023–2031
Figure 47: Latin America Vasopressin Antagonists Market Value Share, by Distribution Channel, 2022 and 2031
Figure 48: Latin America Vasopressin Antagonists Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 49: Latin America Vasopressin Antagonists Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031
Figure 50: Latin America Vasopressin Antagonists Market Value Share, by Country/Sub-region, 2022–2031
Figure 51: Latin America Vasopressin Antagonists Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 52: Middle East & Africa Vasopressin Antagonists Market Value Share, by Drug Type, 2022 and 2031
Figure 53: Middle East & Africa Vasopressin Antagonists Market Attractiveness Analysis, by Drug Type, 2023–2031
Figure 54: Middle East & Africa Vasopressin Antagonists Market Value Share, by Application, 2022 and 2031
Figure 55: Middle East & Africa Vasopressin Antagonists Market Attractiveness Analysis, by Application, 2023–2031
Figure 56: Middle East & Africa Vasopressin Antagonists Market Value Share, by Distribution Channel, 2022 and 2031
Figure 57: Middle East & Africa Vasopressin Antagonists Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 58: Middle East & Africa Vasopressin Antagonists Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031
Figure 59: Middle East & Africa Vasopressin Antagonists Market Value Share, by Country/Sub-region, 2022–2031
Figure 60: Middle East & Africa Vasopressin Antagonists Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 61: Global Vasopressin Antagonists Market Share Analysis, by Company, 2022 (Estimated)
Figure 62: Global Vasopressin Antagonists Market Performance, by Company, 2022
Figure 63: Competition Matrix
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Vasopressin Antagonists Market
*86 figures and 60 tables includes